Journal article

Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA

Madalene A Earp, Linda E Kelemen, Anthony M Magliocco, Kenneth D Swenerton, Georgia Chenevix-Trench, Yi Lu, Alexander Hein, Arif B Ekici, Matthias W Beckmann, Peter A Fasching, Diether Lambrechts, Evelyn Despierre, Ignace Vergote, Sandrina Lambrechts, Jennifer A Doherty, Mary Anne Rossing, Jenny Chang-Claude, Anja Rudolph, Grace Friel, Kirsten B Moysich Show all

HUMAN GENETICS | SPRINGER | Published : 2014

Abstract

Epithelial ovarian cancer (EOC) is a heterogeneous cancer with both genetic and environmental risk factors. Variants influencing the risk of developing the less-common EOC subtypes have not been fully investigated. We performed a genome-wide association study (GWAS) of EOC according to subtype by pooling genomic DNA from 545 cases and 398 controls of European descent, and testing for allelic associations. We evaluated for replication 188 variants from the GWAS [56 variants for mucinous, 55 for endometrioid and clear cell, 53 for low-malignant potential (LMP) serous, and 24 for invasive serous EOC], selected using pre-defined criteria. Genotypes from 13,188 cases and 23,164 controls of Europe..

View full abstract

Grants

Awarded by Canadian Institutes of Health Research


Awarded by American Cancer Society


Awarded by California Cancer Research Program


Awarded by Cancer Research UK


Awarded by Danish Cancer Society


Awarded by German Federal Ministry of Education and Research of Germany, Program of Clinical Biomedical Research


Awarded by Imperial Experimental Cancer Research Centre


Awarded by L & S Milken Foundation; the Lon V. Smith Foundation


Awarded by National Health and Medical Research Council of Australia


Awarded by Polish Ministry of Science and Higher Education


Awarded by state of Baden-Wurttemberg through Medical Faculty of the University of Ulm


Awarded by US Army Medical Research and Material Command


Awarded by Department of Defense Ovarian Cancer Research Program


Awarded by US National Cancer Institute


Awarded by US National Institutes of Health/National Center for Research Resources/General Clinical Research Center


Awarded by US Public Health Service


Awarded by US National Cancer Institute.


Awarded by The US National Cancer Institute


Awarded by DIVISION OF CANCER CONTROL &POPULATION SCIENCE


Awarded by DIVISION OF CANCER PREVENTION AND CONTROL


Awarded by NATIONAL CANCER INSTITUTE


Awarded by NATIONAL CENTER FOR RESEARCH RESOURCES


Awarded by The Francis Crick Institute


Funding Acknowledgements

Funding of constituent studies: This project was funded through grants from the Canadian Institutes of Health Research (MOP-86727, MOP-84340); WorkSafeBC 14, and OvCaRe: BC's Ovarian Cancer Research Team. Funding of the constituent studies was provided by the American Cancer Society (CRTG-00-196-01-CCE); the California Cancer Research Program (00-01389 V-20170, N01-CN25403, 2II0200); Cancer Council Victoria; Cancer Council Queensland; Cancer Council New South Wales; Cancer Council South Australia; Cancer Council Tasmania; Cancer Foundation of Western Australia; the Cancer Institute of New Jersey; Cancer Research UK (C490/A6187, C490/A10119, C490/A10124, C536/A13086, C536/A6689); the Celma Mastry Ovarian Cancer Foundation; the Danish Cancer Society (94-222-52); the ELAN Program of the University of Erlangen-Nuremberg; the Eve Appeal (Oak Foundation); the Fred C. and Katherine B. Andersen Foundation; the German Cancer Research Center; the German Federal Ministry of Education and Research of Germany, Program of Clinical Biomedical Research (01 GB 9401); the Helsinki University Central Hospital Research Fund; Helse Vest; Imperial Experimental Cancer Research Centre (C1312/A15589); the L & S Milken Foundation; the Lon V. Smith Foundation (LVS-39420); the Mayo Foundation; the Mermaid I project; the Minnesota Ovarian Cancer Alliance; the National Health and Medical Research Council of Australia (199600, 209057, 251533, 396414, 400281, and 504715); Nationaal Kankerplan of Belgium; the Norwegian Cancer Society; the Norwegian Research Council; the OHSU Foundation; the Polish Ministry of Science and Higher Education (4 PO5C 028 14, 2 PO5A 068 27); Pomeranian Medical University; Radboud University Medical Center; the Roswell Park Cancer Institute Alliance Foundation; the Royal Marsden Hospital; the Rudolf-Bartling Foundation; the Sigrid Juselius Foundation; the state of Baden-Wurttemberg through Medical Faculty of the University of Ulm (P.685); the UK National Institute for Health Research Biomedical Research Centres at the University of Cambridge and the University College London Hospitals; the US Army Medical Research and Material Command (DAMD17-98-1-8659, DAMD17-01-1-0729, DAMD17-02-1-0666, DAMD17-02-1-0669, W81XWH-10-1-0280); the Department of Defense Ovarian Cancer Research Program (W81XWH-07-1-0449); the US National Cancer Institute (K07-CA095666, K22-CA138563, N01-CN55424, N01-PC067010, N01-PC035137, P01-CA017054, P01-CA087696, P30-CA15083, P50-CA105009, P50-CA136393, R01-CA014089, R01-CA016056, R01-CA017054, R01-CA049449, R01-CA050385, R01-CA054419, R01-CA058598, R01-CA058860, R01-CA061107, R01-CA061132, R01-CA063678, R01-CA063682, R01-CA064277, R01-CA067262, R01-CA071766, R01-CA074850, R01-CA076016, R01-CA080742, R01-CA080978, R01-CA083918, R01-CA087538, R01-CA092044, R01-095023, R01-CA106414, R01CA122443, R01-CA112523, R01-CA114343, R01-CA126841, R01CA136924, R01-CA149429, R03-CA113148, R03-CA115195, R37CA070867, R37-CA70867, U01-CA069417, U01-CA071966 and Intramural research funds); the US National Institutes of Health/National Center for Research Resources/General Clinical Research Center (MO1-RR000056); and the US Public Health Service (PSA-042205).